$5.85 Billion in Sales Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter

Equities analysts expect Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) to post sales of $5.85 billion for the current fiscal quarter, Zacks Investment Research reports. Eight analysts have made estimates for Gilead Sciences’ earnings. The lowest sales estimate is $5.50 billion and the highest is $6.42 billion. Gilead Sciences posted sales of $6.22 billion during the same quarter last year, which would indicate a negative year over year growth rate of 5.9%. The business is scheduled to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Gilead Sciences will report full year sales of $24.64 billion for the current financial year, with estimates ranging from $24.16 billion to $25.77 billion. For the next fiscal year, analysts forecast that the business will report sales of $23.95 billion, with estimates ranging from $23.20 billion to $24.82 billion. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Gilead Sciences.

Gilead Sciences (NASDAQ:GILD – Get Rating) last announced its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.35. Gilead Sciences had a return on equity of 44.98% and a net margin of 16.43%. The company had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.28 billion. During the same period in the prior year, the company earned $2.08 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year.

GILD has been the subject of several recent research reports. Wells Fargo & Company reduced their price target on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a research report on Tuesday, March 22nd. Maxim Group reduced their price target on Gilead Sciences from $88.00 to $84.00 in a research report on Thursday, February 3rd. Barclays reduced their price target on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a research report on Thursday, March 10th. Mizuho reduced their price target on Gilead Sciences from $81.00 to $75.00 and set a “buy” rating for the company in a research report on Tuesday, February 8th. Finally, Truist Financial reduced their price target on Gilead Sciences from $77.00 to $75.00 and set a “hold” rating for the company in a research report on Wednesday, February 2nd. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $72.20.

GILD stock opened at $65.01 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.48 and a quick ratio of 1.30. The stock has a market capitalization of $81.54 billion, a P/E ratio of 18.16, a P/E/G ratio of 0.45 and a beta of 0.38. The business has a 50-day moving average of $61.43 and a 200-day moving average of $65.12. Gilead Sciences has a fifty-two week low of $57.19 and a fifty-two week high of $74.12.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 29th. Stockholders of record on Wednesday, June 15th will be paid a dividend of $0.73 per share. The ex-dividend date is Tuesday, June 14th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.49%. Gilead Sciences’s dividend payout ratio (DPR) is currently 81.56%.

In other news, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction that occurred on Friday, March 11th. The stock was sold at an average price of $58.24, for a total transaction of $211,644.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of GILD. OLD Second National Bank of Aurora boosted its stake in shares of Gilead Sciences by 46.3% during the 3rd quarter. OLD Second National Bank of Aurora now owns 439 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 139 shares during the last quarter. Key Financial Inc lifted its stake in shares of Gilead Sciences by 3.7% during the 4th quarter. Key Financial Inc now owns 4,228 shares of the biopharmaceutical company’s stock valued at $307,000 after buying an additional 151 shares in the last quarter. Trust Investment Advisors lifted its stake in shares of Gilead Sciences by 1.3% during the 4th quarter. Trust Investment Advisors now owns 12,243 shares of the biopharmaceutical company’s stock valued at $889,000 after buying an additional 153 shares in the last quarter. Equitable Holdings Inc. lifted its stake in shares of Gilead Sciences by 0.4% during the 3rd quarter. Equitable Holdings Inc. now owns 41,253 shares of the biopharmaceutical company’s stock valued at $2,882,000 after buying an additional 156 shares in the last quarter. Finally, Certified Advisory Corp increased its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Certified Advisory Corp now owns 14,297 shares of the biopharmaceutical company’s stock valued at $999,000 after acquiring an additional 161 shares during the last quarter. Hedge funds and other institutional investors own 80.16% of the company’s stock.

About Gilead Sciences (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Read More